AusBiotech

Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.

The scientists behind Australia’s first locally developed mRNA COVID-19 vaccine candidate have published a preclinical study demonstrating the vaccine's potential to overcome the issue of ‘immune imprinting.’

Australian biotechnology company Cartherics, which is developing immune cell therapies for cancer and other diseases, has been awarded a US$300,000 G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.

“If you have ovarian cancer, ask your oncologist to consider a test that will help determine whether your cancer is one of just under 50 per cent that might be responsive to new treatment options such as PARP inhibitors," says cancer researcher Professor Anna deFazio.

Australasian Biotechnology is AusBiotech’s official biannual journal, published in September and April. Written by the sector, for the sector highlighting topics such as technology development, manufacturing excellence, sustainability, and strategies to strengthen Australia’s end-to-end life sciences value chain.

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II in humans.

AusBiotech has formalised a new partnership with BioNSW, a rapidly growing not-for-profit organisation dedicated to harnessing the full potential of the New South Wales Life Sciences sector.

Led by BioMelbourne Network, the new initiative brings together expertise from peak industry bodies and companies to create a voice and advocate on behalf of Victorian medtech manufacturers across the key issues impacting the sector. 

PYC Therapeutics (ASX:PYC) has announced it plans to progress investigational drug candidate PYC-002 into human clinical trials for Phelan-McDermid Syndrome.

Neuren Pharmaceuticals (ASX: NEU) has announced that the sale of the Rare Pediatric Disease Priority Review Voucher by its partner Acadia Pharmaceuticals has been completed.

Immutep (ASX:IMM) has announced positive clinical results from Cohort B of the TACTI-003 (KEYNOTEC34) Phase 2b trial.